Is there an exodus underway at Epic?
In this edition of STAT Health Tech: executive departures at Epic Systems, new CEO takes over at Nabla, and more health tech news.
Read full article →Medicare Monitor
Tracking Medicare news, policy, and coverage changes.
STAT+: Broad Institute, partners unveil new initiative to develop gene therapies for rare diseases
The Broad Institute, Boston Children’s Hospital, and Maine’s Jackson Laboratory announced a collaboration to develop rare disease gene therapies.
Read full article →STAT+: Anthropic deepens work with rare disease drugs
Novo Nordisk sues Eli Lilly over GLP-1s, Medicare pricing plans, and more biotech news from The Readout
Read full article →STAT+: Pharmalittle: We’re reading about Novo suing Lilly over ‘deceptive’ ads, a fugitive’s secret life in biotech, and more
Novo Nordisk sued Eli Lilly for allegedly running “deceptive” ads to make its obesity and diabetes drugs appear more effective
Read full article →STAT+: Nabla’s new CEO on plan to gain market share in a competitive AI scribe environment
Ambient scribe developer Nabla said Brian Manning will be the Paris-based company's new CEO as it looks to grow in a highly competitive market.
Read full article →STAT+: Novo Nordisk sues Eli Lilly over GLP-1 drug ads it calls ‘deceptive’
Novo Nordisk sued Eli Lilly for allegedly running a “deceptive” ad campaign that uses “outdated clinical trials” to make its obesity and diabetes drugs appear more effective.
Read full article →A renewed push from the right against abortion pills
The latest on cyclospora, THC sodas at the grocery store, and more health news from Morning Rounds
Read full article →STAT+: Makers of rare disease drugs seek exemption from Trump’s price-cut pilots
A coalition of biotech firms is lobbying to exclude orphan drugs from new federal pilot programs aimed at lowering Medicare drug costs.
Read full article →Opinion: Science and the public are learning the wrong lessons from Covid
“Post-pandemic polarization threatens to lock our memories into attractive, untrue conclusions that will leave us unprotected next time,” write Marc Lipsitch and Sara Cody.
Read full article →Opinion: How a controversial rule could hurt the NIH’s ability to manage risk
The proposed rule could “weaken the NIH’s benign influence over research risks,” writes Doni Bloomfield.
Read full article →Amid nurse shortage, a university rolls out the welcome mat for men
Only about 1 in 8 nurses are men, but their share is growing. A strong job market for nurses and sustained efforts to recruit men into the field have made a difference, including in the South.
Read full article →FDA still focused on Taylor Farms lettuce as Cyclospora source despite retracted test
The FDA retracted its only positive test for cyclospora, the parasite at the center of a multistate outbreak, on Taylor Farms lettuce. But the agency believes lettuce from the brand is still linked.
Read full article →